TCGA-AO-A03T-01A-21R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 71
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.420
- KRAS_SIGNALING_DN+0.350
- ESTROGEN_RESPONSE_LATE+0.330
- INTERFERON_ALPHA_RESPONSE+0.280
- BILE_ACID_METABOLISM+0.270
- PEROXISOME+0.210
- ESTROGEN_RESPONSE_EARLY+0.200
- MYOGENESIS+0.190
- OXIDATIVE_PHOSPHORYLATION+0.190
- INTERFERON_GAMMA_RESPONSE+0.180
Top 10 suppressed
- MITOTIC_SPINDLE-0.450
- TGF_BETA_SIGNALING-0.410
- UV_RESPONSE_DN-0.380
- WNT_BETA_CATENIN_SIGNALING-0.330
- PROTEIN_SECRETION-0.300
- INFLAMMATORY_RESPONSE-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- NOTCH_SIGNALING-0.250
- ANDROGEN_RESPONSE-0.230
- G2M_CHECKPOINT-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LL-A6FQ-01A-11R-A31O-07 | — | B | 0.810 |
| 2 | TCGA-E2-A572-01A-13R-A31O-07 | — | B | 0.803 |
| 3 | TCGA-UL-AAZ6-01A-11R-A41B-07 | — | B | 0.763 |
| 4 | TCGA-LL-A9Q3-01A-11R-A41B-07 | — | B | 0.743 |
| 5 | edef6762-dd96-4284-81e6-2e128af287fa | — | — | 0.740 |
| 6 | TCGA-LL-A5YM-01A-11R-A28M-07 | — | B | 0.734 |
| 7 | TCGA-AQ-A54O-01A-11R-A266-07 | — | B | 0.733 |
| 8 | MDT-AP-2389 | Med | Medulloblastoma | 0.731 |
| 9 | TCGA-75-7031-01A-11R-1949-07 | — | cohortA3 | 0.726 |
| 10 | 84f39507-9883-4bab-98f9-8bd72d2aee7b | — | — | 0.718 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.330 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |